Biotech Breakthrough Could Create A $11.4 Trillion Opportunity (SPONSORED POST)

TM editors' note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence.

A little-known biotech company is poised to potentially earn millions in revenue with the planned upcoming release of a breakthrough technology that could prevent massive numbers of strokes with a simple test that is affordable and accessible to the average American.

A Multi-Billion-Dollar Problem with a $49,000 Answer

Stroke statistics are shocking: Globally, every year 15 million people suffer a stroke. Of these, some 6 million are killed, while 5 million are rendered permanently disabled. In the U.S. alone, nearly 800,000 people suffer from strokes annually—and someone dies of a stroke every 4 minutes.

Until now, there has been no cost-effective way to screen for Ischemia, the leading indicator of a stroke, which cost the U.S. government alone tens of billions of dollars a year. That could be about to change, thanks to a breakthrough technology from CVR Medical (TSX:CVM.V ; OTC:CRRVF). The company’s debut, game-changing medical device has been quietly in development for 10 years, and now it’s about to charge out of the gate, hoping to take the market by storm upon FDA market clearance.  

What 3D seismic imagery did for super quick discoveries in the oil and gas industry, CVR’s  sensory system could do for the medical industry.

CVR’s Carotid Stenotic Scan (CSS) is a tool to detect stenosis within the Carotid Arteries, potentially offering patients and caregivers a device for early detection in a quick and repeatable manner. Unlike other comparative modalities, the CSS was designed to function without the assistance of a certified technician.  These three facts combine to create one of the potentially biggest—and most lucrative--phenomena in recent medical equipment market history.

The CSS makes a connection between fluid flow and sub-sonic frequencies to detect arterial disease or blockage. Blood flowing through the carotid arteries produces wave patterns which are shaped and altered by the presence of irregularities on the inner artery walls. CVR’s advanced technology captures these wave patterns and analyzes them mathematically with patented algorithms. After a brief test, the analysis is complete, offering a way to potentially identify those at risk of a stroke and arming the healthcare provider with the information necessary to prevent the deadly event. For investors, medical providers, insurers, and the public at large, the secondary benefit is that this new innovation has a price tag that renders testing up to 50 times cheaper than many tools on the market today.

1 2 3 4
View single page >> |

Legal Disclaimer/Disclosure: This piece is an advertorial and has been paid for. This document is not and should not be construed as an offer to sell or the solicitation of an offer to ...

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Alpha Stockman 3 years ago Member's comment

Sounds like a potential opportunity. I would like to read more about this stock? $CRRVF

Terrence Howard 3 years ago Member's comment

Interesting read, thanks.

Angry Old Lady 3 years ago Member's comment

One must always take sponsored posts with a grain of salt, but I think this stock is worth a closer look. There's not much coverage on it though. Where can I find more?

David M. Green 3 years ago Member's comment

Impressed with the far reaching impact of this technological breakthrough. Could bode well for the stock. What competitors are there?

Barry Hochhauser 3 years ago Member's comment

Are there any reviews of this product by actual doctors. Would love to know if its as impressive as it sounds.

Cynthia Decker 3 years ago Member's comment

Very impressed with what #CVR Medical has built here. There certainly seems to be a valid market for its technology. But what about potential competitors? Are there any competing products in the pipeline from other companies which could post a threat?

Dick Kaplan 3 years ago Member's comment

Excellent question. I agree this article is very impressive, but we clearly have to take it with a grain of salt. Would love to learn more about $CRRVF and if any one has any good reason why I should NOT invest in the stock. Any counter point views?

Dan Jackson 3 years ago Member's comment

While I certainly would like to see some other opinions on $CRRVF, at this price, I wouldn't mind picking up a few shares.

Flat Broke 3 years ago Member's comment

"This isn’t a one trick pony. CVR’s CSS is only the first in the application of the technology."

What are some of the other applications? $CRRVF

Harry Goldstein 3 years ago Member's comment

Applying 3D seismic imagery to the medical industry? Brilliant. $CRRVF